Daily non-political popular news in brief.
Revlimid data presented at ASCO stands to change the way physicians treat multiple myeloma
06-04-2007 · EurekAlert!Findings from a Phase III study by the Eastern Cooperative Oncology Group (ECOG) were presented yesterday at the American Society of Clinical Oncology (ASCO) meeting in Chicago and demonstrate the impressive survival benefits of using Revlimid (lenalidomide) with reduced doses of the steroid dexamethasone.
Read more »
Keywords: revlimid, data, presented, asco, stands, change, way, physicians, treat, multiple, myeloma, stand, physician
« Previous | Next »
Similar news on "Revlimid data presented at ASCO stands to change the way physicians treat multiple myeloma":
- New multiple myeloma treatment induced total remission in 33 percent of patients
06-04-2007 · EurekAlert!
A study presented yesterday in the ASCO Annual Meeting shows that the alternating treatment of two drugs before autologous bone marrow transplantation improves the post-transplantation response. The largest anti-myeloma effect of drugs was assessed in the earliest periods of medication, and this fact sets the basis for new research lines on the reduction of the total number of treatment cycles in order to allow an earlier transplantation. This would result in costs and medication reduction.
Similar news · Read more »
- Studies at cancer conference show new therapies changing outlook for blood cancer patients
12-08-2006 · EurekAlert!
The International Myeloma Foundation (IMF) -- conducting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians -- today noted that multiple studies presented at the 2006 Annual Meeting of the American Society of Hematology (ASH) illustrate the breadth of the gains being made in the treatment of multiple myeloma and related blood cancers.
Similar news · Read more »
- One-fourth of HIV patients believe their doctors stigmatize them
08-31-2007 · EurekAlert!
Physicians might want to be extra careful about how they treat HIV-infected patients —not just in the clinical sense but in the way they behave toward them. Even the perception that physicians are stigmatizing patients for carrying the virus that causes AIDS can discourage these individuals from seeking proper medical care, according to a new UCLA study.
Similar news · Read more »
- Targeted, oral agent Enzastaurin shows favorable results
06-02-2007 · EurekAlert!
Enzastaurin, an investigational targeted, oral agent under development by Eli Lilly and Company, showed encouraging results in treating patients with late-stage non-small cell lung cancer (NSCLC), according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).
Similar news · Read more »
- Drug combination proves effective against myeloma in Phase I trial
12-11-2006 · EurekAlert!
Two "new generation" drugs for the bone marrow cancer multiple myeloma may work even better together than they do individually, according to the results of a multicenter Phase I clinical trial to be presented by Dana-Farber Cancer Institute scientists at the annual meeting of the American Society of Hematology in Orlando, Fla.
Similar news · Read more »
- New therapeutic options for newly diagnosed multiple myeloma patients
12-10-2007 · EurekAlert!
Mayo Clinic researchers today presented results of a phase II trial of myeloma induction therapy -- a first step therapy designed to reduce cancer cells numbers -- with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D) showing an improved response over the traditional lenalidomide-dexamethasone (L-Dex) therapy.
Similar news · Read more »
- Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
06-02-2007 · EurekAlert!
ALIMTA (pemetrexed for injection) showed additional utility in the treatment of the most diagnosed type of cancer, according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). Results from a Phase III study suggest that a first-line ALIMTA-based regimen may deliver less toxicity than a commonly used therapy in advanced non-small cell lung cancer (NSCLC). ALIMTA is manufactured and marketed by Eli Lilly and Company.
Similar news · Read more »
- Mellow in Europe, crazy in America
02-26-2007 · EurekAlert!
Reed canarygrass stays put in Europe where it's native, but is aggressively expanding into wetlands across North America. Using this grass as a model, University of Vermont researchers have revealed a new way that some plants become invasive: Multiple introductions of the same species from numerous regions lead to new strains which grow more aggressively than the original plants. With climate change, this kind of invader may become increasingly successful.
Similar news · Read more »
- A new technology for cancer screening listens for the signs of cancer
09-18-2007 · EurekAlert!
Cancer-sensing devices built as cheaply and efficiently as wristwatches -- using many of the same operating principles -- could change the way clinicians detect, treat and monitor cancer in patients. Researchers from the Georgia Institute of Technology have created an acoustic sensor that can report the presence of small amounts of mesothelin, a molecule associated with a number of cancers including mesothelioma, as they attach to the sensor's surface.
Similar news · Read more »
- Argon conclusion: Researchers reassess theories on formation of Earth's atmosphere
09-19-2007 · EurekAlert!
Geochemists at Rensselaer Polytechnic Institute are challenging commonly held ideas about how gases are expelled from the Earth. Their theory, which is described in the Sept. 20 issue of the journal Nature, could change the way scientists view the formation of Earth's atmosphere and those of our distant neighbors, Mars and Venus. Their data throw into doubt the timing and mechanism of atmospheric formation on terrestrial plants.
Similar news · Read more »
